Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: Effects of ester, injection site and injection volume

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 93-102

  Minto, Charles F ^a   Howe, Christopher ^b   Wishart, Susan ^b   Conway, Ann J ^b   Handelsman, David J ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIS OIL; ESTER; INHIBIN; NANDROLONE DECANOATE; NANDROLONE PHENPROPIONATE; TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTOID MUSCLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; GLUTEUS MAXIMUS MUSCLE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANABOLIC AGENTS; HUMANS; INHIBINS; INJECTIONS; MALE; NANDROLONE; TESTOSTERONE; VEHICLES;

EID: 0030924263     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. AL-HINDAWI, M. K., JAMES, K. C. AND NICHOLLS, P. J.: Influence of solvent on the availability of testosterone propionate from oily, intramuscular injections in the rat. J. Pharm. Pharmacol 39: 90-95, 1986.
2. BALLARD, B. E.: Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J. Pharm. Sci. 57: 357-378, 1968.
3. BALLARD, B. E.; Prolonged-action pharmaceuticals. In Remingtons Pharmaceutical Sciences, pp. 1594-1613, Mack Publishing Co., Easton, PA, 1980.
4. BEAL, S. L. AND SHELNER, L. B.: NONMEM User's Guide, parts I-VII, University of California Press, San Francisco, 1992.
5. BEDBRKA, J., TAKEMORI, A. E. AND MILLER, J. W.: Absorption rates of various substances administered intramuscularly. Eur. J. Pharmacol. 15: 132-136, 1971.
6. BEHRE, H. M., KLEIN, B., STEINMEYER, E., MCGREGOR, G. P., VOIGT, K. AND NIESCHLAG, E.: Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J. Clin. Endocrinol. Metab. 75: 393-398, 1992.
7. BEHRE, H. M., OBERPENNING, F. AND NIESCHLAO, E.: Comparative pharmacokinetics of androgen preparations: Application of computer analysis and simulation. In Testosterone: Action Deficiency Substitution, ed. by E. Nieschlag and H. M. Behre, pp. 115-135, Springer-Verlag, Berlin, 1990.
8. BELKIEN, L., SCHURMEYER, T., HANO, R., GUNNARSON, P. O. AND NIESCHLAG, E.: Pharmacokinetics of 19-nortestosterone esters in normal men. J. Steroid Biochem. 5: 623-629, 1985.
9. BROWN, W., WILDER, V. AND SCHWARTZ, P.: A study of oils used for intramuscular injections. J. Lab. Clin. Med. 29: 259-264, 1944.
10. BURGER, H. G.: Inhibin, Reprod. Med. Rev. 1: 1-20, 1992.
11. CHAMBERS, J. M. AND HASTIE, T. J., EDS.: Statistical Models in S. Chapman and Hall, New York, 1993.
12. COCKSHOTT, W. P., THOMPSON, G. T., HOWLETT, L. J. AND SEELEY, E. T.: Intramuscular or intralipomatous injections? N. Engl. J. Med. 307: 356-358, 1982.
13. CRAWFORD, B. A. AND HANDELSMAN, D. J.: Failure of recombinant growth hormone or insulin-like growth factor-I to influence gonadotrophin sensitivity of the non-human primate testis in-vivo. Eur. J. Endocrinol, 131: 405-412, 1994.
14. DAYNEKA, N. L., GARG, V. AND JUSKO, W. J.: Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21: 457-478, 1993.
15. DIXON, W.: BMDP Statistical Software Manual, University of California Press, Berkeley. CA, 1992.
16. DONC, Q., HAWKER, F., MCWILLIAM, D., BANGAH, M., BURGER, H. AND HANDELSMAN, D. J.: Circulating inhibin and testosterone levels in men with critical illness. Clin. Endocrinol. 36: 399-404, 1992.
17. EVANS, E. F., PROCTOR, J. D., FRATKIN, M. J., VELANDIA, J. AND WASSERMAN, A. J.: Blood flow in muscle groups and drug absorption. Clin. Pharmacol. Ther 17: 44-47, 1975.
18. FUJIOKA, M., SHINOHARA, Y., BABA, S., IRIE, M. AND INDUE, K.: Pharmacokinetic properties of testosterone propionate in normal men, J. Clin. Endocrinol. Metab. 63: 1361-1364, 1986.
19. GANDY, H. M.: Androgens. In Endocrinology of Pregnancy, ed. by F. Fuchs and A. Klopper, pp. 123-156, Harper & Row, Hagerstown, MD, 1977.
20. GAHZA-FLORES, J.: Pharmacokinetics of once-a-month injectable contraceptives, Contraception 49: 347-359, 1994.
21. GIBALDI, M. AND PERRIER, D.: Pharmacokinetics, Marcel Dekker, New York, 1982.
22. GREENBLATT, D. J. AND KOCH-WESER, J.: Intramuscular injection of drugs. N. Engl. J. Med. 295: 542-546, 1976.
23. HANDELSMAN, D. J.: Testosterone and other androgens: Physiology, pharmacology and therapeutic use. In Endocrinology, ed. by L. J. DeGroot, pp. 2351- 2361, W. B. Saunders, Philadelphia. 1994.
24. HANDELSMAN, D. J., PARLEY, T. M. M., PEREGOUDOV, A., WAITES, G. M. H. AND WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Factors in the nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil. Steril. 63: 125-133, 1995.
25. HANDELSMAN, D. J., SPALIVIERO, J. A. AND PHIHPARD, A. F.: Highly vectorial secretion of inhibin by primate Sertoli cells in vitro. J. Clin. Endocrinol. Metab. 71: 1235-1238, 1990.
26. JUNKMAN, K.: Long-acting steroids in reproduction. Recent Prog. Horm. Res. 13: 380-419, 1957.
27. JUSKO, W. J. AND Ko, H. C.: Physiologic indirect response models characterise diverse types of pharmacodynamic effects. Clin. Pharmacol, Ther. 56: 406-419, 1994.
28. MANDEMA, J. W., VEROTTA, D. AND SHEINER, L. B.: Building population pharma- cokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20: 511-528, 1992.
29. McLACHLAN, R. I., FINKEL, D. M., BREMNER, W. J. AND SNYDER, P. J.: Serum inhibin concentrations before and during gonadotropin treatment in men with hypogonadotropic hypogonadism: Physiological and clinical implications. J. Clin. Endocrinol. Motab. 70: 1414-1419, 1990.
30. MODDERMAN, E. S. M., MERKUS, F. W. H. M., ZUIDEMA, J., HILBERS, H. W. AND WAHNUORFF, T.: Sex differences in the absorption of dapsone after intramuscular injection. Int. J. Leprosy 51: 359-365, 1983.
31. NIEHCHLAG, E. AND BEHKE, H. M.: Pharmacology and clinical uses of testosterone. In Testosterone: Action Deficiency Substitution, ed. by E. Nieachlag and H. M. Behre, pp. 92-114, Springer-Verlag, Berlin, 1990.
32. NIESCHLAC, E., CUPPER, H. J., WIEGELMAN, W. AND WICKINGS, E. J.: Bioavailability and LH suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm. Res. 7: 138-145, 1976.
33. SCHULTE-BEERBUHL, M. AND NIESCHLAG, E.: Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate, Fertil. Steril. 33: 201-203, 1980.
34. SCHURMEYER, T. AND NIESCHLAG, E.: Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels. Int. J. Androl. 7: 181-187, 1984.
35. TANAKA, T., KOBAYASHI, H., OKAMURA, K., MURANISHI, S. AND SEZAKI, H.: Intramuscular absorption of drugs from oily solutions in the rat. Chem. Pharm. Bull. (Tokyo) 22: 1275-1284, 1974.
36. VAN DER VIES, J.: On the mechanism of action of nandrolone phenylpropionate and nandrolone decanoate in rats. Acta Endocrinol. 49: 271-282, 1965.
37. VINING, R. F.: Testosterone radioimmunoassay: Rapid extraction technique for steroids based on kieselguhr mini-columns. Steroids 36: 149-159, 1980.
38. WALLACE, E. M., Gow, S. M. AND WU, F. C. W.: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I. Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol. and inhibin concentrations, J. Clin. Endocrinol. Metab. 77: 290-293, 1993.
39. WIJNAND, H. P., BOSCH, A. M. G. AND DONKER, C. M.: Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers. Acta Endocrinol. Suppl. 271: 19-30, 1985.
40. WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 955-959, 1990.
41. WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril. 60: 1062-1068, 1993.
42. ZUIDEMA, J., PIETERS, F. A. J. M. AND DUCHATEAU, G. S. M. J. E.: Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int. J. Pharm. 47: 1-12, 1988.